Core Insights - Strata Critical Medical, Inc. reported a strong Q4 2025 with organic growth of 35%, exceeding expectations and leading to a full-year performance that surpassed guidance on all fronts [1][24] - The company is raising its revenue and adjusted EBITDA guidance for 2026 due to strong volumes and new customer acquisitions [1][29] Financial Performance - Full-year 2025 revenue reached $197.1 million and adjusted EBITDA was $14.1 million, both exceeding the high end of guidance [24] - Q4 2025 revenue was $66.8 million, driven by logistics growth of 35.3% to $49.2 million compared to $36.4 million in the prior year [24][27] - Clinical revenue in Q4 2025 was $17.6 million, significantly up from $2.8 million in Q3 2025, reflecting the impact of the Keystone acquisition [24][25] Growth Strategy - Continued acquisitions of smaller businesses are a key part of the company's strategy to accelerate growth and expand geographically [5][15] - The company expects to maintain an average annualized adjusted EBITDA growth rate of at least 30% over the coming years, driven by successful execution of its M&A strategy [15][16] Regulatory Environment - Recent regulatory changes are seen as beneficial for Strata Critical Medical, particularly in incentivizing the pursuit of medically complex organs [8][10] - The company is well-positioned with a customer base that is over-indexed to larger, more sophisticated transplant centers, which are favored under new regulations [10][11] Operational Highlights - The company ended the year with a fleet of approximately 30 dedicated or owned aircraft and plans to add two new owned aircraft to support new geographies in 2026 [12][13] - Logistics gross profit increased by 39.5% to $10.6 million in Q4 2025, driven by strong revenue growth and improved gross margins [27] Future Outlook - The company raised its 2026 revenue guidance range to $260–$275 million from $255–$270 million previously, and adjusted EBITDA guidance to $29–$33 million from $28–$32 million [29] - Despite a modest sequential revenue decline expected in Q1 2026, the company anticipates a sequential improvement in revenue and margin in the second quarter and the latter half of the year [31]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported revenue of $66.8 million, driven by logistics growth, with organic growth of 35.3% to $49.2 million compared to $36.4 million in the prior year [22][24] - Full year 2025 revenue and adjusted EBITDA were $197.1 million and $14.1 million respectively, both exceeding the high end of guidance [22][24] - Adjusted EBITDA rose to $7 million in Q4 2025, up from $1.1 million in the prior year period [25] Business Line Data and Key Metrics Changes - Logistics revenue in Q4 2025 was $49.2 million, reflecting a 35.3% increase year-over-year [22][24] - Clinical revenue was $17.6 million in Q4 2025, significantly up from $2.8 million in Q3 2025, attributed to the Keystone acquisition [22][24] - Gross profit increased 90% to $14.4 million in Q4 2025, with gross margin rising to 21.6% from 20.8% in the prior year [24][25] Market Data and Key Metrics Changes - Approximately 20% of revenue is generated from Organ Procurement Organizations (OPOs), with Tier One OPOs representing 2.4 times the revenue of Tier Three OPOs [10] - The company is well-positioned to benefit from regulatory changes incentivizing the pursuit of medically complex organs, particularly from DCD donors [9][10] Company Strategy and Development Direction - The company is focusing on acquisitions of smaller businesses to accelerate growth and expand geographically [5][6] - A significant part of the strategy includes enhancing the logistics services for transplant clinical cases, which contributed to revenue growth [7][10] - The company plans to maintain an average annualized adjusted EBITDA growth rate of at least 30% over the coming years [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the future, raising guidance for 2026 revenue to $260 million-$275 million and adjusted EBITDA to $29 million-$33 million [27] - The company noted that while there was a soft January for the industry, they have seen continued strength in logistics trips and clinical cases [29][30] - Management is optimistic about the integration of the Keystone acquisition and the positive feedback from customers [30] Other Important Information - The company ended the year with approximately 30 dedicated or owned aircraft and plans to add two new owned aircraft to support new regions [12][13] - The company has a $30 million asset-based credit facility with JPMorgan, providing flexibility for future acquisitions [15] Q&A Session Summary Question: Update on continuous distribution policy and stakeholders involved - Management stated that continuous distribution is still the goal for all organs, with lungs already transitioned, but the timeline for hearts and livers is uncertain due to regulatory focus on other issues [32][33] Question: Breakdown of the transplant value chain and service usage - Management indicated that transplant clinical services have slightly higher profit margins than non-transplant clinical services, with efforts to convert more clinical customers to use logistics services [36][38] Question: Acquisition pipeline and adjacent offerings - The company plans to announce acquisitions as they close and is focused on increasing scale and national footprint through product servicing [41][42] Question: Impact of weather on operations - Management noted that severe weather in the Northeast has caused unusual disruptions, but overall confidence for the year remains strong [71][72] Question: Impact of higher oil prices - Management clarified that fuel price increases would be passed through to customers and would not significantly impact the company's cost structure [73][74]